Table 3.
Twenty-nine high-grade chondrosarcomas and associated alterations in the key players of the pRb and p53 pathways
| L-number | pRb pathway | p53 pathway | |||||
|---|---|---|---|---|---|---|---|
| p16 | CDK4 | Cyclin D1 | p21 | MDM2 | p53 | ||
| 1 | 147 | + | − | − | − | n/a | − |
| 2 | 164 | + | + | + | + | − | − |
| 3 | 171 | − | + | − | + | − | − |
| 4 | 172 | − | + | + | + | n/a | − |
| 5 | 181 | − | + | − | − | − | − |
| 6 | 182 | + | + | − | + | − | − |
| 7 | 184 | − | + | + | + | + | + |
| 8 | 187 | − | + | + | − | − | − |
| 9 | 190 | − | + | − | − | n/a | − |
| 10 | 250 | + | − | + | + | − | + |
| 11 | 253 | − | − | n/a | − | + | n/a |
| 12 | 260 | + | − | + | + | − | + |
| 13 | 265 | + | − | + | + | + | + |
| 14 | 266 | − | − | + | − | − | + |
| 15 | 278 | + | + | − | + | + | − |
| 16 | 286 | − | − | − | + | n/a | − |
| 17 | 304 | + | − | + | + | + | − |
| 18 | 333 | − | − | + | + | − | + |
| 19 | 536 | + | − | + | − | − | − |
| 20 | 629 | + | + | + | + | − | + |
| 21 | 654 | − | − | + | + | − | + |
| 22 | 795 | − | + | + | + | + | + |
| 23 | 802 | + | + | − | + | − | − |
| 24 | 813 | + | + | n/a | n/a | − | n/a |
| 25 | 822 | + | − | + | + | − | + |
| 26 | 861 | − | + | − | − | n/a | − |
| 27 | 903 | + | − | + | + | − | − |
| 28 | 908 | + | + | + | + | + | + |
| 29 | 1066 | − | + | − | + | + | − |
| Total | Negative | Positive | Positive | Negative | Positive | Positive | |
| 14/29(48%) | 16/29 (55%) | 17/27(62%) | 8/28(28%) | 8/24(33%) | 11/27(41%) | ||
| Summary | 28/29(96%) | 21/29 (72%) | |||||
+ and – indicate positive and negative results, respectively. Immunohistochemical results for p16 were published previously [15]. n/a: data not available.